Hi Kpax, all I can say is that the exact A-Syn species has not been revealed to investors as far as I know. But, unlike the MABs being used by AZ and BIIB to target A-Syn directly for PD, PBT434 does not directly attack A-Syn like those monoclonal antibodies.
If you look at the Fairpark p1 trial results using a related drug to stop/slow PD with a chelator(DFP). Their current FairparkII trial is not even looking at A-Syn.
My guess is by repairing the iron balance, A-Syn is prevented from aggregation.
PBT434 inhibits alpha- synuclein in the brain., page-17
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $3.516K | 1.112M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 75 | 108230584 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 151421887 | 64 |
View Market Depth
| Last trade - 13.21pm 06/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |